What can I expect if I join the study?

If you qualify and choose to join the study and sign the informed consent form, you will be asked to attend a screening visit with the study doctor. At this visit, you will undergo tests and procedures to determine if you are a good match for continuing in the study.

- The study includes three periods: screening, study treatment, and follow-up. Study duration will vary from person to person depending on your response to the investigational medications and subsequent medications.
- You will be randomly assigned to 1 of 3 study treatment groups: study treatment Arm A, B, or C. Each group will receive a different combination of investigational medications.
- In the study treatment period, each study treatment cycle will last 21 days. During the first day of each cycle (for Arms A and C, for the first cycle it will be the 1st and 2nd days), you will be infused with investigational medications. You will also take one daily investigational medication if you are in study treatment Arm A. After the study treatment period, there will be follow-up visits every 12 weeks (your visits may be replaced with phone calls).
- Qualified participants may receive investigational medications and some study-required care at no cost. The study will not pay for other medical care or current medication(s) needed to support your daily health care routine.

Can I change my mind?

Yes. You can quit the study at any time, for any reason. Even if you begin the study, you can change your mind at any point.

For more information about this clinical research study, contact:

844-963-4668

MARIPOSA-2

Janssen Research & Development, LLC
61186372NSC3002_ENG03
Version 1.0, 09July2021

Janssen

What if your Lung Cancer path included a different approach?

Learn more about the MARIPOSA 2 clinical research study that is evaluating a combination of investigational medications in addition to approved chemotherapy for adults with EGFR-positive advanced non-small-cell lung cancer (NSCLC).

A clinical research study to evaluate a combination of investigational medications in addition to approved chemotherapy in adults with EGFR-positive locally advanced or metastatic non-small-cell lung cancer is now enrolling.

Evaluating Investigational Medication through Clinical Research

What is a clinical research study?

A clinical trial, also called a clinical research study, is a carefully designed scientific evaluation of an investigational medication or treatment. Clinical trials are conducted by doctors and researchers.

Why is clinical research important?

Clinical research helps doctors and scientists determine if an investigational medication or therapies are safe and/or effective for use in humans to potentially treat a condition, disease or disorder. Clinical studies often require a large number of volunteers to participate in a single study, and sometimes thousands are needed to obtain reliable information.

What is Informed Consent?

"Informed consent" is a process of information exchange before an adult agrees to participate in research. Potential research participants will be asked to read and sign an informed consent document, but will also be given instructions, verbally and in writing, question/answer sessions and other reading materials to assure the potential study participants' understanding and willingness to voluntarily enroll in the research.

So, before you agree to volunteer for the study, the study doctor or staff is required to explain all the details of the study, which will include the potential risks and benefits, and address your questions. After all of your questions have been answered, and if you wish to participate, then you will sign a document called the informed consent form to ensure:

- You agree to volunteer.
- You understand the study, including the study procedures, potential risks and side effects of the investigational medications.
- You understand that you can leave the study at any time, for any reason.

If you don't understand the document or what is expected of you, you should continue to ask questions and talk with the study doctor, your family or others that you trust, until you feel you understand.

Purpose of the MARIPOSA 2 study

The purpose of this clinical research study is to evaluate the effectiveness of a combination of investigational medications in addition to approved chemotherapy in people with EGFR-positive locally advanced or metastatic non-small-cell lung cancer.

Am I eligible?

You may be able to participate in the MARIPOSA 2 study if you:

- Are 18 years of age or older
- Have been diagnosed with non-small-cell lung cancer that has tested positive for EGFR Exon 19 deletion or Exon 21 L858R substitution
- Have experienced disease progression on or after taking osimertinib

Additional eligibility criteria will be assessed by the study doctor or staff during the screening process prior to you being enrolled in the study and receiving any investigational medications. Not all individuals may qualify to participate in the research.